Missak Haigentz

8PUBLICATIONS
55CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyCancer geneticsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 26, 2026
Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy.

|May 05, 2026
Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9.

|Jul 31, 2023
Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087).

Missak Haigentz, Jeannette Y Lee, Elizabeth Y Chiao

|Feb 23, 2023
Waiting for Big Changes in Limited-Stage Small-Cell Lung Cancer: For Now, More of the Same.

Matthew P Deek, Missak Haigentz, Salma K Jabbour

|Dec 01, 2022
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Charu Aggarwal, Nabil F Saba, Alain Algazi

|Nov 03, 2019
Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance.

Nabil F Saba, Zhuo Gerogia Chen, Missak Haigentz

Pageof 2

Frequent Collaborators

2 joint publications

Juan P Rodrigo

1 joint publications

Marc Hamoir

1 joint publications

Primoz Strojan

1 joint publications

Antti A Mäkitie